Weiyu Ni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Weiyu Ni has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Panyang Shen
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications- Shunwu Fan
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Shuying Shen
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - An Qin
Department of Orthopaedics, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Ninth People' s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
1 shared publication Gang Liu
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publicationHaitao Zhang
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Chondrocytes reprogram chromatin in hypoxic microenvironments to activate CADM1-AS1/HDAC1 complex-mediated anti-inflammation signals
Maintaining chondrocyte homeostasis is crucial for the effective treatment of osteoarthritis. Chondrocytes reside in a hypoxic environment under physiological conditions. This study, conducted exclusively in male mice, examines the association between epigenetics and chondrocyte homeostasis and observes significant alterations in histone acetylation in chondrocytes under hypoxic conditions. We identify a key enhancer element that regulates the long non-coding RNA CADM1-AS1, which is essential for cartilage homeostasis. This work elucidates a mechanism of epigenetic modulation that contributes to chondrocyte dysfunction in osteoarthritis. Further mechanistic investigations show that CADM1-AS1 recruits histone deacetylase complexes to suppress the transcriptional activation of NOS2, thereby affecting amino acid metabolism in chondrocytes. Conditional knockout of CADM1-AS1 in chondrocytes accelerates osteoarthritis development in mice. Using a hybrid exosome delivery system, we successfully modulate the expression of CADM1-AS1 and effectively reduce cartilage damage. Collectively, these findings reveal the importance of epigenetic regulation via CADM1-AS1-mediated histone deacetylation in the pathogenesis of osteoarthritis. Thus, CADM1-AS1 represents a potential therapeutic target for reducing cartilage damage in osteoarthritis and improving disease management.
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessChondrocytes reprogram chromatin in hypoxic microenvironments to activate CADM1-AS1/HDAC1 complex-mediated anti-inflammation signals
Maintaining chondrocyte homeostasis is crucial for the effective treatment of osteoarthritis. Chondrocytes reside in a hypoxic environment under physiological conditions. This study, conducted exclusively in male mice, examines the association between epigenetics and chondrocyte homeostasis and observes significant alterations in histone acetylation in chondrocytes under hypoxic conditions. We identify a key enhancer element that regulates the long non-coding RNA CADM1-AS1, which is essential for cartilage homeostasis. This work elucidates a mechanism of epigenetic modulation that contributes to chondrocyte dysfunction in osteoarthritis. Further mechanistic investigations show that CADM1-AS1 recruits histone deacetylase complexes to suppress the transcriptional activation of NOS2, thereby affecting amino acid metabolism in chondrocytes. Conditional knockout of CADM1-AS1 in chondrocytes accelerates osteoarthritis development in mice. Using a hybrid exosome delivery system, we successfully modulate the expression of CADM1-AS1 and effectively reduce cartilage damage. Collectively, these findings reveal the importance of epigenetic regulation via CADM1-AS1-mediated histone deacetylation in the pathogenesis of osteoarthritis. Thus, CADM1-AS1 represents a potential therapeutic target for reducing cartilage damage in osteoarthritis and improving disease management.
- 10 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (6) , eade5584
Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis
Osteoarthritis (OA) is a degenerative disease with a series of metabolic changes accompanied by many altered enzymes. Here, we report that the down-regulated dimethylarginine dimethylaminohydrolase-1 (DDAH1) is accompanied by increased asymmetric dimethylarginine (ADMA) in degenerated chondrocytes and in OA samples. Global or chondrocyte-conditional knockout of ADMA hydrolase DDAH1 accelerated OA development in mice. ADMA induces the degeneration and senescence of chondrocytes and reduces the extracellular matrix deposition, thereby accelerating OA progression. ADMA simultaneously binds to SOX9 and its deubiquitinating enzyme USP7, blocking the deubiquitination effects of USP7 on SOX9 and therefore leads to SOX9 degradation. The ADMA level in synovial fluids of patients with OA is increased and has predictive value for OA diagnosis with good sensitivity and specificity. Therefore, activating DDAH1 to reduce ADMA level might be a potential therapeutic strategy for OA treatment.
- 10 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (6) , eade5584
Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis
Osteoarthritis (OA) is a degenerative disease with a series of metabolic changes accompanied by many altered enzymes. Here, we report that the down-regulated dimethylarginine dimethylaminohydrolase-1 (DDAH1) is accompanied by increased asymmetric dimethylarginine (ADMA) in degenerated chondrocytes and in OA samples. Global or chondrocyte-conditional knockout of ADMA hydrolase DDAH1 accelerated OA development in mice. ADMA induces the degeneration and senescence of chondrocytes and reduces the extracellular matrix deposition, thereby accelerating OA progression. ADMA simultaneously binds to SOX9 and its deubiquitinating enzyme USP7, blocking the deubiquitination effects of USP7 on SOX9 and therefore leads to SOX9 degradation. The ADMA level in synovial fluids of patients with OA is increased and has predictive value for OA diagnosis with good sensitivity and specificity. Therefore, activating DDAH1 to reduce ADMA level might be a potential therapeutic strategy for OA treatment.